$TNYA
Tenaya Therapeutics Inc

2022 Q4 Form 10-Q Financial Statement

#000095017022024521 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.802M $7.540M $5.356M
YoY Change 68.91% 40.78% 171.6%
% of Gross Profit
Research & Development $25.75M $23.76M $12.94M
YoY Change 22.88% 83.54% 52.64%
% of Gross Profit
Depreciation & Amortization $2.117M $2.087M $746.0K
YoY Change 167.64% 179.76% 18.23%
% of Gross Profit
Operating Expenses $34.55M $31.30M $18.30M
YoY Change 32.05% 71.03% 75.09%
Operating Profit -$31.30M -$18.30M
YoY Change 71.03% 75.09%
Interest Expense $1.037M $596.0K $23.00K
YoY Change 1447.76% 2491.3% 228.57%
% of Operating Profit
Other Income/Expense, Net -$3.000K $602.0K $38.00K
YoY Change -94.44% 1484.21% -75.8%
Pretax Income -$33.52M -$30.70M -$18.26M
YoY Change 28.16% 68.09% 77.39%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$33.52M -$30.70M -$18.26M
YoY Change 28.16% 68.09% 77.39%
Net Earnings / Revenue
Basic Earnings Per Share -$0.74 -$0.68
Diluted Earnings Per Share -$0.61 -$0.74 -$679.0K
COMMON SHARES
Basic Shares Outstanding 41.37M 41.36M 26.90M
Diluted Shares Outstanding 41.36M 26.90M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $186.5M $149.5M $280.5M
YoY Change -25.78% -46.71%
Cash & Equivalents $95.27M $34.49M $117.1M
Short-Term Investments $91.26M $115.0M $163.4M
Other Short-Term Assets $7.227M $7.617M $4.357M
YoY Change 78.09% 74.82%
Inventory
Prepaid Expenses $4.044M
Receivables
Other Receivables
Total Short-Term Assets $193.8M $157.1M $284.8M
YoY Change -24.12% -44.85%
LONG-TERM ASSETS
Property, Plant & Equipment $51.03M $52.19M $30.89M
YoY Change 18.62% 68.96%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $17.70M
YoY Change
Other Assets $4.793M $4.650M $3.528M
YoY Change 33.92% 31.8%
Total Long-Term Assets $85.19M $69.24M $46.97M
YoY Change 44.81% 47.41%
TOTAL ASSETS
Total Short-Term Assets $193.8M $157.1M $284.8M
Total Long-Term Assets $85.19M $69.24M $46.97M
Total Assets $278.9M $226.3M $331.8M
YoY Change -11.22% -31.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.578M $5.312M $6.171M
YoY Change -10.66% -13.92%
Accrued Expenses $10.66M $8.388M $5.607M
YoY Change 17.72% 49.6%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $24.25M $17.72M $13.69M
YoY Change 11.36% 29.39%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $228.0K $223.0K $96.00K
YoY Change 25.27% 132.29%
Total Long-Term Liabilities $228.0K $223.0K $96.00K
YoY Change 25.27% 132.29%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.25M $17.72M $13.69M
Total Long-Term Liabilities $228.0K $223.0K $96.00K
Total Liabilities $35.57M $29.98M $28.10M
YoY Change -0.26% 6.72%
SHAREHOLDERS EQUITY
Retained Earnings -$279.2M -$245.7M -$129.4M
YoY Change 79.51% 89.88%
Common Stock $7.000K $4.000K $4.000K
YoY Change 75.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $243.4M $196.3M $303.7M
YoY Change
Total Liabilities & Shareholders Equity $278.9M $226.3M $331.8M
YoY Change -11.22% -31.79%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$33.52M -$30.70M -$18.26M
YoY Change 28.16% 68.09% 77.39%
Depreciation, Depletion And Amortization $2.117M $2.087M $746.0K
YoY Change 167.64% 179.76% 18.23%
Cash From Operating Activities -$22.68M -$27.56M -$16.66M
YoY Change 38.75% 65.43% 74.71%
INVESTING ACTIVITIES
Capital Expenditures $795.0K -$4.064M -$5.008M
YoY Change -106.33% -18.85% 2991.36%
Acquisitions
YoY Change
Other Investing Activities $6.769M $35.10M -$163.4M
YoY Change -113.53% -121.48%
Cash From Investing Activities $5.974M $31.03M -$168.4M
YoY Change -109.55% -118.43% 103866.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 77.49M 6.000K 190.3M
YoY Change -369080.95% -100.0% 519.89%
NET CHANGE
Cash From Operating Activities -22.68M -27.56M -16.66M
Cash From Investing Activities 5.974M 31.03M -168.4M
Cash From Financing Activities 77.49M 6.000K 190.3M
Net Change In Cash 60.78M 3.484M 5.192M
YoY Change -176.98% -32.9% -75.28%
FREE CASH FLOW
Cash From Operating Activities -$22.68M -$27.56M -$16.66M
Capital Expenditures $795.0K -$4.064M -$5.008M
Free Cash Flow -$23.48M -$23.49M -$11.65M
YoY Change 518.96% 101.67% 24.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001858848
dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40656
dei Entity Registrant Name
EntityRegistrantName
TENAYA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3789973
dei Entity Address Address Line1
EntityAddressAddressLine1
171 Oyster Point Boulevard
dei Entity Address Address Line2
EntityAddressAddressLine2
5th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
825-6990
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
TNYA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
41374508
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4650000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4126000
CY2022Q3 us-gaap Assets
Assets
226310000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34494000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38129000
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
114956000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
213171000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7617000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4058000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
157067000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
255358000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
52194000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43020000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
12399000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11685000
CY2021Q4 us-gaap Assets
Assets
314189000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5312000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10721000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8388000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9059000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4016000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1994000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
17716000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21774000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12043000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
13707000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
223000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
182000
CY2022Q3 us-gaap Liabilities
Liabilities
29982000
CY2021Q4 us-gaap Liabilities
Liabilities
35663000
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
442773000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
434196000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-767000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-141000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-245682000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-155533000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
196328000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
278526000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
226310000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
314189000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23758000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12944000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
68789000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33440000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26895716
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7540000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5356000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22282000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13202000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
31298000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
18300000
us-gaap Operating Expenses
OperatingExpenses
91071000
us-gaap Operating Expenses
OperatingExpenses
46642000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-31298000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18300000
us-gaap Operating Income Loss
OperatingIncomeLoss
-91071000
us-gaap Operating Income Loss
OperatingIncomeLoss
-46642000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
596000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
23000
us-gaap Investment Income Interest
InvestmentIncomeInterest
917000
us-gaap Investment Income Interest
InvestmentIncomeInterest
41000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
31000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
602000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
38000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
922000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
72000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30696000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18262000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-90149000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-46570000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-30696000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-18262000
us-gaap Net Income Loss
NetIncomeLoss
-90149000
us-gaap Net Income Loss
NetIncomeLoss
-46570000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-28000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-23000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-626000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-23000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30724000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18285000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-90775000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46593000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.75
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41358296
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41358296
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26895716
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3012000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-108000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41309812
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41309812
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9808162
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9808162
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
278526000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17000
CY2022Q1 tnya Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
6000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2094000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-490000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-31056000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
249097000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
230000
CY2022Q2 tnya Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
5000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-28397000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
223867000
CY2022Q3 tnya Stock Issued During Period Value Stock Options Exercised And Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfRestrictedStockUnits
6000
CY2022Q3 tnya Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
5000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3174000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-28000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-30696000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
196328000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-81315000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
29000
CY2021Q1 tnya Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
9000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
432000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-13098000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-93943000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
31000
CY2021Q2 tnya Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
9000
CY2021Q2 tnya Notes Receivable From Stockholders
NotesReceivableFromStockholders
75000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
502000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-15210000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-108536000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
268000
CY2021Q3 tnya Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
8000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
968000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-23000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-18262000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
303699000
us-gaap Profit Loss
ProfitLoss
-90149000
us-gaap Profit Loss
ProfitLoss
-46570000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4350000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2170000
tnya Amortization Of Premium On Marketable Securities
AmortizationOfPremiumOnMarketableSecurities
76000
tnya Amortization Of Premium On Marketable Securities
AmortizationOfPremiumOnMarketableSecurities
6000
us-gaap Share Based Compensation
ShareBasedCompensation
8280000
us-gaap Share Based Compensation
ShareBasedCompensation
1902000
tnya Gain Loss On Write Offs And Disposal Of Property And Equipment
GainLossOnWriteOffsAndDisposalOfPropertyAndEquipment
-27000
tnya Gain Loss On Write Offs And Disposal Of Property And Equipment
GainLossOnWriteOffsAndDisposalOfPropertyAndEquipment
-4000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1510000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
743000
tnya Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
3278000
tnya Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
3029000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
672000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
3063000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1803000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2518000
tnya Increase Decrease In Accrued Liabilities And Other Current Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
2051000
tnya Increase Decrease In Accrued Liabilities And Other Current Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
1729000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2147000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-952000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
13000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
77000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-81742000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44465000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
19835000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12567000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
108737000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
163417000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
206250000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
77678000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-175984000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
188605000
tnya Proceeds From Exercise Of Stock Options And Employee Stock Purchase Plan
ProceedsFromExerciseOfStockOptionsAndEmployeeStockPurchasePlan
281000
tnya Proceeds From Exercise Of Stock Options And Employee Stock Purchase Plan
ProceedsFromExerciseOfStockOptionsAndEmployeeStockPurchasePlan
343000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
13000
tnya Proceeds From Repayments On Notes Receivable From Stockholders
ProceedsFromRepaymentsOnNotesReceivableFromStockholders
75000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
281000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
208991000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3783000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11458000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
38676000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
129082000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
34893000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
117624000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34494000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117077000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
399000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
547000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34893000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
117624000
tnya Conversion Of Convertible Preferred Stock To Common Stock Upon Completion Of Initial Public Offering
ConversionOfConvertiblePreferredStockToCommonStockUponCompletionOfInitialPublicOffering
220754000
tnya Offering Costs Related To Initial Public Offering Included In Accounts Payable And Accrued And Other Current Liabilities
OfferingCostsRelatedToInitialPublicOfferingIncludedInAccountsPayableAndAccruedAndOtherCurrentLiabilities
64000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
263000
us-gaap Lease Cost
LeaseCost
4213000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3677000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-245700000
us-gaap Net Income Loss
NetIncomeLoss
-90100000
us-gaap Net Income Loss
NetIncomeLoss
-46600000
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
149500000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reclassification</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain prior year balances have been reclassified in order to conform to current year presentation for the condensed balance sheets. These reclassifications have no effect on the previously reported financial position.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accrued liabilities, income tax valuation allowance and stock-based compensation. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Management </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">bases its estimates on historical experience, the current economic environment, and on</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">various </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</span></p>
tnya Impairment Charges On Marketable Securities Related To Other Than Temporary
ImpairmentChargesOnMarketableSecuritiesRelatedToOtherThanTemporary
0
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
65769000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
52445000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2224000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
8558000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13575000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9425000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
52194000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43020000
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2100000
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
700000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4300000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2200000
CY2022Q3 tnya Accrued Compensation And Related Expenses
AccruedCompensationAndRelatedExpenses
4607000
CY2021Q4 tnya Accrued Compensation And Related Expenses
AccruedCompensationAndRelatedExpenses
3667000
CY2022Q3 tnya Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
2567000
CY2021Q4 tnya Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
2023000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
574000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
344000
CY2022Q3 tnya Accrued Property And Equipment
AccruedPropertyAndEquipment
155000
CY2021Q4 tnya Accrued Property And Equipment
AccruedPropertyAndEquipment
2863000
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
485000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
162000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8388000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9059000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1090000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
702000
us-gaap Operating Lease Cost
OperatingLeaseCost
2624000
us-gaap Operating Lease Cost
OperatingLeaseCost
1662000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
319000
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
306000
us-gaap Variable Lease Cost
VariableLeaseCost
910000
us-gaap Variable Lease Cost
VariableLeaseCost
796000
CY2022Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
244000
CY2021Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
585000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
709000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
1755000
CY2022Q3 us-gaap Lease Cost
LeaseCost
1653000
tnya Cash Paid For Leases Included In Operating Cash Outflows
CashPaidForLeasesIncludedInOperatingCashOutflows
4597000
tnya Cash Paid For Leases Included In Operating Cash Outflows
CashPaidForLeasesIncludedInOperatingCashOutflows
4423000
tnya Cash Paid For Amounts Included In The Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities
2978000
tnya Cash Paid For Amounts Included In The Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities
1872000
CY2021Q3 us-gaap Lease Cost
LeaseCost
1593000
us-gaap Lease Cost
LeaseCost
4243000
CY2022Q3 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P5Y8M12D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.092
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.95
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1315000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5223000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3910000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2445000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1386000
CY2022Q3 tnya Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
6905000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
21184000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5125000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
16059000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P10Y
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.96
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.97
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.96
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.96
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.97
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.95
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.03
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.029
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.036
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.009
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.012
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.016
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.036
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.006
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.012
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3174000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
968000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8280000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1902000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5273925
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2571036

Files In Submission

Name View Source Status
0000950170-22-024521-index-headers.html Edgar Link pending
0000950170-22-024521-index.html Edgar Link pending
0000950170-22-024521.txt Edgar Link pending
0000950170-22-024521-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tnya-20220930.htm Edgar Link pending
tnya-20220930.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
tnya-ex31_1.htm Edgar Link pending
tnya-ex31_2.htm Edgar Link pending
tnya-ex32_1.htm Edgar Link pending
tnya-20220930_htm.xml Edgar Link completed
tnya-20220930_cal.xml Edgar Link unprocessable
tnya-20220930_def.xml Edgar Link unprocessable
tnya-20220930_lab.xml Edgar Link unprocessable
tnya-20220930_pre.xml Edgar Link unprocessable